Pmv Pharmaceuticals Inc (PMVP) Stock Price, Quote & News

Company Profile

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is rezatapopt, an orally available small molecule that potently and selectively correct p53 misfolding caused by p53 mutation, Y220C, while sparing wild-type p53. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmace...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 642 6670

Website: www.pmvpharma.com

Address:

400 Alexander Park Drive, Suite 301, Princeton, United States

WallStArb Jul. 29 at 3:18 PM

$PMVP exited the majority of this name as its close to next cash - I expect the data to be positive there’s not much chance to disappoint but after 100% gain in 7 weeks I sold more than 2/3 - it has some upside though if the data shows efficacy see my post from 2 months ago. Risk/reward is biased to risk here or a sell the news event on ok data

0 · Reply

smartkarma Jul. 28 at 4:40 AM

$PMVP | SSI Newsletter: PMVP Trial Catalyst, YORKU Trading Split, CPPTL Extension, GLXZ Merger, LUNA Updates "PMV Pharmaceuticals is in a Phase 2 trial for cancer therapy, with interim results expected mid-2025, and potential value realization through strategic review due to a large net cash position." - Special Situation Investments (Special Situation Investments) Read more: https://www.smartkarma.com/insights/ssi-newsletter-pmvp-trial-catalyst-yorku-trading-split-cpptl-extension-glxz-merger-luna-updates

0 · Reply

Zaga64 Jul. 24 at 6:10 PM

$PMVP I sold early @ $1.33 but I can't complain PMVP was one of my best trade of the year. GLTA

0 · Reply

DARKP00L Jul. 24 at 5:58 PM

$PMVP this stock is attracting a lot of interest. Be prepared for possible changes!

0 · Reply

smartkarma Jul. 23 at 12:49 PM

$PMVP | PMV Pharmaceuticals: Evaluating Cash Position and Strategic Options Amid Upcoming Trial Results and Shareholder Pressure "PMVP's market cap is $72M, with $166M in cash as of Q1, offering substantial discount to net cash." - Special Situation Investments (Special Situation Investments) Read more: https://www.smartkarma.com/insights/pmv-pharmaceuticals-evaluating-cash-position-and-strategic-options-amid-upcoming-trial-results-and-shareholder-pressure

0 · Reply

Zaga64 Jul. 15 at 2:28 PM

$PMVP Completely out of PMVP but GLTA

1 · Reply

Honest_InvestorZ Jul. 10 at 6:28 PM

$PMVP buy 1.20 and hold. Expect big pop on data

0 · Reply

Zaga64 Jul. 8 at 5:46 PM

$PMVP $1.33 Deal or no deal!

1 · Reply

WeThePeople102 Jul. 8 at 5:41 PM

$PMVP bought 3k shares @ $0.90 , sold 2k shares @1.20. Now my 1k shares just cost $0.30. I think I will hold these shares until the final stage.

0 · Reply

Zaga64 Jul. 8 at 3:01 PM

$PMVP Great result = $2+ Bad or underwhelming result = $.65

0 · Reply

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

Mar 3, 2025, 8:00 AM EST - 5 months ago

PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights

May 29, 2024, 7:00 AM EDT - 1 year ago

Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator

May 9, 2024, 8:00 AM EDT - 1 year ago

PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights

Mar 27, 2024, 8:00 AM EDT - 1 year ago

PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors

Mar 18, 2024, 4:01 PM EDT - 1 year ago

PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer

Feb 29, 2024, 4:01 PM EST - 1 year ago

PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights

Jan 18, 2024, 4:01 PM EST - 1 year ago

PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway

Jan 5, 2024, 4:01 PM EST - 1 year ago

PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development

Nov 14, 2023, 6:50 PM EST - 1 year ago

PMV Pharmaceuticals: In A Stronger Position Now Than Before, At A Lower Price

Nov 9, 2023, 8:00 AM EST - 1 year ago

PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights

Oct 12, 2023, 12:30 PM EDT - 1 year ago

PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation

Oct 11, 2023, 12:00 PM EDT - 1 year ago

PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar

Sep 20, 2023, 4:05 PM EDT - 2 years ago

PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Aug 30, 2023, 9:20 AM EDT - 2 years ago

PMV Pharmaceuticals: A 5-Month Run-Up Is Justified

Aug 9, 2023, 8:00 AM EDT - 2 years ago

PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Highlights

Jun 6, 2023, 4:01 PM EDT - 2 years ago

PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference

May 10, 2023, 8:00 AM EDT - 2 years ago

PMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Highlights

Mar 1, 2023, 8:00 AM EST - 2 years ago

PMV Pharmaceuticals Reports Full Year 2022 Financial Results and Corporate Highlights

Feb 28, 2023, 4:05 PM EST - 2 years ago

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in March

Nov 22, 2022, 8:00 AM EST - 2 years ago

PMV Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference

Nov 8, 2022, 8:00 AM EST - 2 years ago

PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights

Nov 4, 2022, 8:00 AM EDT - 2 years ago

PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors

Aug 9, 2022, 8:00 AM EDT - 3 years ago

PMV Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights

Jul 18, 2022, 8:00 AM EDT - 3 years ago

PMV Pharmaceuticals Announces a Clinical Trial Collaboration with Merck to Evaluate PC14586 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors

Jun 7, 2022, 12:00 PM EDT - 3 years ago

PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C Mutation

May 26, 2022, 5:05 PM EDT - 3 years ago

PMV Pharmaceuticals Announces Initial PC14586 Phase 1 Clinical Data to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 10, 2022, 7:30 AM EDT - 3 years ago

PMV Pharmaceuticals Reports First Quarter 2022 Financial Results and Corporate Highlights

Apr 27, 2022, 10:30 AM EDT - 3 years ago

PMV Pharmaceuticals to Present PC14586 Phase 1 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Mar 1, 2022, 7:15 AM EST - 3 years ago

PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

Feb 28, 2022, 8:00 AM EST - 3 years ago

PMV Pharmaceuticals to Participate in the 42nd Annual Cowen Health Care Conference

Feb 3, 2022, 8:00 AM EST - 3 years ago

PMV Pharmaceuticals to Participate in the Guggenheim Healthcare Talks 2022 Oncology Day

Jan 6, 2022, 8:00 AM EST - 3 years ago

PMV Pharma Announces Changes to its Board of Directors

Nov 22, 2021, 8:00 AM EST - 4 years ago

PMV Pharma to Present at the Evercore ISI 4th Annual HealthCONx Conference

Nov 12, 2021, 7:15 AM EST - 4 years ago

PMV Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights

Sep 2, 2021, 8:00 AM EDT - 4 years ago

PMV Pharmaceuticals to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

Aug 13, 2021, 8:00 AM EDT - 4 years ago

PMV Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights

Jun 9, 2021, 8:00 AM EDT - 4 years ago

PMV Pharmaceuticals Announces Participation at the Bank of America Securities 2021 Napa Biopharma Virtual Conference

May 14, 2021, 8:00 AM EDT - 4 years ago

PMV Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Highlights

May 5, 2021, 8:00 AM EDT - 4 years ago

PMV Pharmaceuticals Announces Participation at the Bank of America Healthcare Conference

Apr 10, 2021, 1:31 PM EDT - 4 years ago

PMV Pharma Presents Late-Breaking Preclinical Data on Lead Product Candidate PC14586 at the American Association for Cancer Research Annual Meeting 2021

Apr 6, 2021, 8:00 AM EDT - 4 years ago

PMV Pharma Strengthens Board of Directors with Appointment of Dr. Charles Baum

Mar 10, 2021, 4:31 PM EST - 4 years ago

PMV Pharmaceuticals Announces Presentation of PC14586 Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021

Mar 3, 2021, 4:01 PM EST - 4 years ago

PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights

Feb 16, 2021, 8:00 AM EST - 4 years ago

PMV Pharma Appoints p53 Pioneer Dr. Guillermina Lozano to Scientific Advisory Board

Nov 24, 2020, 5:00 PM EST - 5 years ago

PMV Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx Conference

Nov 23, 2020, 8:00 AM EST - 5 years ago

PMV Pharma Doses First Patient in Phase 1/2 Study of PC14586, a First-in-Class Precision Oncology Therapy That Targets Mutant p53

Nov 13, 2020, 8:00 AM EST - 5 years ago

PMV Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights

Oct 6, 2020, 4:16 PM EDT - 5 years ago

Andreas Halvorsen Jumps on PMV Pharmaceuticals

Sep 29, 2020, 4:05 PM EDT - 5 years ago

PMV Pharma Announces Closing of $243.5 Million Initial Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

WallStArb Jul. 29 at 3:18 PM

0 · Reply

smartkarma Jul. 28 at 4:40 AM

0 · Reply

Zaga64 Jul. 24 at 6:10 PM

$PMVP I sold early @ $1.33 but I can't complain PMVP was one of my best trade of the year. GLTA

0 · Reply

DARKP00L Jul. 24 at 5:58 PM

$PMVP this stock is attracting a lot of interest. Be prepared for possible changes!

0 · Reply

smartkarma Jul. 23 at 12:49 PM

0 · Reply

Zaga64 Jul. 15 at 2:28 PM

$PMVP Completely out of PMVP but GLTA

1 · Reply

Honest_InvestorZ Jul. 10 at 6:28 PM

$PMVP buy 1.20 and hold. Expect big pop on data

0 · Reply

Zaga64 Jul. 8 at 5:46 PM

$PMVP $1.33 Deal or no deal!

1 · Reply

WeThePeople102 Jul. 8 at 5:41 PM

$PMVP bought 3k shares @ $0.90 , sold 2k shares @1.20. Now my 1k shares just cost $0.30. I think I will hold these shares until the final stage.

0 · Reply

Zaga64 Jul. 8 at 3:01 PM

$PMVP Great result = $2+ Bad or underwhelming result = $.65

0 · Reply

Zaga64 Jul. 8 at 2:48 PM

$PMVP I missed on PROK which is up 280% today on positive phase 2 analysis. PMVP Interim analysis from Phase 2 PYNNACLE trial expected anytime.

0 · Reply

Zaga64 Jul. 8 at 2:13 PM

$PMVP I'm taking some profit and keeping some for a spike like PROK.

0 · Reply

Zaga64 Jul. 8 at 2:11 PM

$PMVP $1.27 Very nice.

0 · Reply

Raxothus Jul. 3 at 7:38 PM

EOD CONTINUATION WATCHLIST - 07/03/25 Focused on stocks with volume, VWAP strength, and potential premarket continuation. $RAYA solid trend and hold above VWAP, controlled RSI, strong grind into close — top watch $IPA big move today, held VWAP with 21% gain, but RSI hot, needs volume to push again $PMVP quiet strength, 7% VWAP stretch and solid volume, possible sleeper setup $RAY micro float, above VWAP, decent volume but needs reclaim and follow-through $THTX high volume but no late push, watching only if it gaps with news Looking for gap and VWAP hold tomorrow. Clean reclaim setups only — no volume, no entry. Happy 4th of July. #VWAP #Continuation #SmallCaps #DayTrading #SniperSetup

0 · Reply

Zaga64 Jul. 3 at 5:07 PM

$PMVP Nice close $1.19

0 · Reply

Zaga64 Jul. 2 at 7:42 PM

$PMVP Interim analysis from Phase 2 PYNNACLE trial expected anytime.

0 · Reply

Zaga64 Jul. 2 at 3:31 PM

$PMVP Phase 2 PYNNACLE trial expected anytime.

0 · Reply

Zaga64 Jun. 30 at 3:23 PM

$PMVP Broke the support so be careful here.

0 · Reply

Zaga64 Jun. 29 at 10:54 PM

$PMVP Interim analysis from Phase 2 PYNNACLE trial expected mid-2025. Cash of $165.8 million as of March 31, 2025.

0 · Reply

WallStArb Jun. 16 at 4:46 PM

$PMVP look for a high volume flush into next 2 weeks prior to Q2 end

1 · Reply

Zaga64 Jun. 16 at 3:14 PM

$PMVP Just to let you know on Friday 27th June – Russell Reconstitution is final after the close of the US equity markets. I will be hunting for the good ones at the end of that day.

0 · Reply

Zaga64 Jun. 16 at 1:05 PM

$PMVP I'm making big $$$ on my high risk stocks SONM and TNMG. All the profit will be coming to my low risk PMVP.

0 · Reply

Market Cap	74.81M
Revenue (ttm)	0.00
Net Income (ttm)	-58.71M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	74,400
Avg Vol	319,218
Day's Range	N/A - N/A
Shares Out	51.95M
Stochastic %K	54%
Beta	1.49
Analysts	Strong Sell
Price Target	$5.80